Gallium 68-labeled FAPI-PET promising for biliary tract cancer detection: Study
China: Gallium 68-labeled fibroblast-activation protein inhibitor (FAPI)-PET imaging is superior to current methods for more accurate staging of biliary tract cancer (BTC), thereby improving treatment decision making, states a recent study in Radiology. In previous studies, Gallium 68–labeled fibroblast-activation protein inhibitor (68Ga-FAPI) is imaging for tumor detection that...
China: Gallium 68-labeled fibroblast-activation protein inhibitor (FAPI)-PET imaging is superior to current methods for more accurate staging of biliary tract cancer (BTC), thereby improving treatment decision making, states a recent study in Radiology.
In previous studies, Gallium 68–labeled fibroblast-activation protein inhibitor (68Ga-FAPI) is imaging for tumor detection that represents a promising alternative to fluorine 18 fluorodeoxyglucose (18F-FDG). Lianjun Lan, a radiologist at the Affiliated Hospital of Southwest Medical University in Luzhou, and colleagues, therefore, aimed to compare the potential efficacy of 68Ga-FAPI PET/CT with that of 18F-FDG PET/CT for detecting primary tumor and nodal and distant metastases in biliary tract cancer and to explore the impact (tumor staging) of 68Ga-FAPI compared with 18F-FDG on clinical management of BTC in a single-center prospective clinical study.
The study was performed at the Affiliated Hospital of Southwest Medical University between June 2020 and June 2021. Patients with BTC underwent both 68Ga-FAPI and 18F-FDG PET/CT. Histopathologic examination, morphologic imaging, and/or follow-up imaging served as the reference standard.
The paired-sample t-test was used to compare the maximum standardized uptake value (SUVmax) of the primary tumor and nodal and distant metastases between 18F-FDG and 68Ga-FAPI PET/CT.
Key findings of the study include:
· Eighteen participants with primary or recurrent BTC were evaluated (mean age, 61 years ± 10 [SD]).
· The sensitivity of 68Ga-FAPI PET/CT was higher than that of 18F-FDG PET/CT for detecting primary tumors (16 of 16 [100%] vs 13 of 16 [81%]), nodal metastases (41 of 42 [98%] vs 35 of 42 [83%]), and distant metastases (99 of 99 [100%] vs 78 of 99 [79%]).
· 68Ga-FAPI PET/CT resulted in new oncologic findings in 10 of 18 participants and upgraded tumor staging or restaging in five of 18 participants compared with 18F-FDG PET/CT.
· 68Ga-FAPI PET/CT demonstrated higher sensitivity than 18F-FDG PET/CT in inflammatory processes secondary to tumor-related obstruction (seven of eight [88%] vs one of eight [13%]).
· 68Ga-FAPI showed lower average SUVmax in inflammatory processes than in oncologic lesions (4.9 ± 2.6 vs 10.0 ± 4.6, respectively).
To conclude, 68Ga-FAPI PET/CT for tumor staging showed potential for more accurate staging of biliary tract cancer, thereby improving treatment decision making.
Lan L, Zhang S, Xu T, Liu H, Wang W, Feng Y, Wang L, Chen Y, Qiu L. Prospective Comparison of 68Ga-FAPI versus 18F-FDG PET/CT for Tumor Staging in Biliary Tract Cancers. Radiology. 2022 May 17:213118. doi: 10.1148/radiol.213118. Epub ahead of print. PMID: 35579524.
Medha, MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at firstname.lastname@example.org. Contact no. 011-43720751